ICUI

ICU Medical, Inc. - 10-Q Filing Summary

Business Context and Reporting Period

This is a Quarterly Report (Form 10-Q) for ICU Medical, Inc., a Delaware corporation, for the period ended September 30, 2004. The company develops, manufactures, and markets disposable medical connection systems for intravenous (I.V.) therapy applications, including the CLAVE connector and Punctur-Guard blood collection needles. The company operates principally in one business segment.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Net sales decreased 36% in Q3 2004 and 21% year-to-date (YTD) compared to 2003. The primary driver was a significant reduction in purchases by major customer Hospira, Inc. (formerly Abbott Laboratories) as they reduced inventory levels of CLAVE products.
• Operating Loss in Q3: The company reported an operating loss of $2.1 million in Q3 2004, compared to an operating income of $6.5 million in Q3 2003. This was caused by reduced sales volume leading to $2.9 million in unabsorbed overhead costs.
• Increased Expenses: Operating expenses increased 48% in Q3 2004. This included a one-time charge of $1.2 million for in-process research and development (IPR&D) related to a new investment, as well as increased costs for patent litigation and Sarbanes-Oxley compliance.
• Inventory Build-up: Inventories increased by $6.2 million (from $3.4M to $9.6M) as the company built finished goods inventory in anticipation of future orders that did not materialize at expected levels due to Hospira's inventory reduction.

Guidance, Outlook, and Risks

• Outlook: Management expects a net loss for the fourth quarter of 2004 due to continued inventory reduction by Hospira and resulting unabsorbed overhead. However, the company expects to remain profitable for the full year 2004.
• Customer Concentration: Hospira accounted for 56% of revenue in the first nine months of 2004. The company expects this percentage to decrease in Q4 2004 but return to 2003 levels in 2005 once Hospira resumes normal purchasing.
• Product Strategy: The company is diversifying away from reliance on CLAVE products by expanding custom I.V. systems and new product lines (e.g., Punctur-Guard). Sales of custom I.V. systems increased 18% YTD.
• Risks:
  • Continued inventory reduction by Hospira impacting production levels and margins.
  • Competition from Cardinal Health's acquisition of Alaris Medical Systems.
  • Patent litigation outcomes against competitors (B. Braun and Alaris).
  • Success of new product development and FDA approvals for upcoming launches in 2005.
• Unusual Items: A $1.2 million charge for IPR&D was recorded in September 2004 following a $2.5 million investment in a company developing a heart disease screening device.

Investor Verification Checklist

• Hospira Inventory Cycle: Verify the timeline for Hospira's inventory reduction and the expected resumption of normal purchasing levels in 2005.
• Unabsorbed Overhead: Assess the impact of fixed manufacturing costs on future margins if production volumes remain depressed.
• Patent Litigation: Monitor the status of infringement lawsuits against B. Braun and Alaris, as these are critical to protecting the CLAVE product line.
• Inventory Valuation: Review the $9.6 million inventory balance for potential write-downs given the lower-than-anticipated sales volume.
• New Product Pipeline: Track the progress of the new heart disease screening device investment and the FDA approval status of new connectors and diabetes products scheduled for 2005.